Autophagy-independent function of Beclin 1 in Breast Cancer
Autophagy-independent function of Beclin 1 in Breast Cancer
批准号:
8828848
负责人:
LESLIE M SHAW
金额:
$5.32万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2018-04-30
关键词:
AreaAttentionAutophagocytosisBifidobacterium longum BIF proteinBiological MarkersBreastBreast CarcinomaCancer PatientCell SurvivalCellsClinicalClinical TrialsCombined Modality TherapyComplexDataDevelopmentDown-RegulationEarly EndosomeEndocytosisEndosomesGenesGenomic InstabilityGoalsGrowthGrowth Factor ReceptorsHomologous GeneHumanInsulin-Like-Growth Factor I ReceptorInvestigationLipidsLysosomesMalignant Epithelial CellMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMembrane Protein TrafficMitochondriaMusNeoplasm MetastasisOrganellesPathway interactionsPatient SelectionPatientsPlayPremalignantProcessPrognostic MarkerProteinsProto-Oncogene Proteins c-aktReceptor ActivationReceptor SignalingRegulationResearchRoleSignal PathwaySignal TransductionTumor Suppressor GenesTumor Suppressor ProteinsVesicleYeastscancer typeimprovedin vivomalignant breast neoplasmnovelnovel strategiespreventpublic health relevancereceptortraffickingtumortumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The novel hypothesis to be examined in this proposal is that Beclin 1 plays an autophagy-independent role in breast cancer through the regulation of endocytic trafficking and the promotion of IGF-1R signaling. Beclin 1 expression is frequently decreased in human tumors, including breast cancer, and decreased expression in mice promotes tumorigenesis, establishing Beclin 1 as a haploinsufficient tumor suppressor gene. Although much research has focused on the role of Beclin 1 in autophagy as the mechanism by which it exerts its tumor suppressor action, alternative functions of Beclin 1 that could contribut to its role in cancer have received less attention. This is significant because Beclin 1 is an essential component of the core complex that regulates not only autophagy, but also endocytic trafficking, which can impact growth factor receptor signaling. In this regard, the applicant made the novel discovery that loss of Beclin 1 enhances IGF-1R activation and downstream signaling to AKT in breast carcinoma cells and that these changes in signaling are associated with increased growth and invasion. The significance of the IGF-1R signaling pathway for breast cancer is underscored by the fact that expression of phosphorylated IGF-1R is a prognostic indicator of reduced patient survival. The clinical importance of the IGF-1R and the need to develop improved approaches for identifying patients to be treated with IGF-1R-targeted therapies highlight the importance of investigating further the novel Beclin 1-mediated mechanism for regulating IGF-1R signaling that the applicant has identified and deciphering its contribution to breast cancer. Preliminary data support an autophagy-independent mechanism for the involvement of Beclin 1 in the regulation of IGF-1R signaling and point toward a mechanism involving the control of endocytic trafficking of the receptor. Further investigation is warranted to understand how the spatial and temporal control of receptor signaling by this essential membrane trafficking pathway contributes to tumor progression. To investigate the hypothesis that Beclin 1 controls breast cancer progression through the autophagy- independent regulation of IGF-1R endocytic trafficking, the applicant will: 1) Establish the role o Beclin 1 in the regulation IGF-1R signaling. The hypothesis that loss of Beclin 1 sustains IGF-1R/IRS-2 signaling by preventing early endosome maturation and subsequent downregulation of the activated receptor by lysosomal degradation will be examined; 2) Investigate the hypothesis that Beclin 1 suppresses breast carcinoma progression through its control of IGF-1R signaling. The hypothesis that sustained activation of the IGF-1R upon loss of Beclin 1 expression enhances survival, invasion and metastasis of breast carcinomas will be examined. The correlation between Beclin 1 expression and IGF-1R/IRS-2/AKT signaling in the pre-malignant mammary gland and human breast tumors will also be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adaptor protein function in breast cancer
-
批准号:10355519
-
项目类别:
-
资助金额:$38.18万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Insulin regulation of breast cancer stem cells
-
批准号:10661633
-
项目类别:
-
资助金额:$16.42万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Adaptor protein function in breast cancer
-
批准号:10614393
-
项目类别:
-
资助金额:$36.7万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
IRS function in breast cancer progression
-
批准号:10177899
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Insulin regulation of breast cancer stem cells
-
批准号:10454136
-
项目类别:
-
资助金额:$16.42万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Insulin regulation of breast cancer stem cells
-
批准号:10227661
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Adaptor protein function in breast cancer
-
批准号:10115640
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
IRS function in breast cancer progression
-
批准号:9899215
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
IRS function in breast cancer progression
-
批准号:10656330
-
项目类别:
-
资助金额:$37.55万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Adaptor protein function in breast cancer
-
批准号:9889069
-
项目类别:
-
资助金额:$38.69万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Insulin regulation of breast cancer stem cells
-
批准号:9797802
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2019
-
负责人:LESLIE M SHAW
-
依托单位:
Autophagy-independent function of Beclin 1 in Breast Cancer
-
批准号:8592964
-
项目类别:
-
资助金额:$34.55万
-
财政年份:2013
-
负责人:LESLIE M SHAW
-
依托单位:
Autophagy-independent function of Beclin 1 in Breast Cancer
-
批准号:8830944
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2013
-
负责人:LESLIE M SHAW
-
依托单位:
Autophagy-independent function of Beclin 1 in Breast Cancer
-
批准号:8692704
-
项目类别:
-
资助金额:$33.71万
-
财政年份:2013
-
负责人:LESLIE M SHAW
-
依托单位:
IRS-2 Function in Tumor Progression and Metastasis
-
批准号:8259779
-
项目类别:
-
资助金额:$33.11万
-
财政年份:2010
-
负责人:LESLIE M SHAW
-
依托单位:
IRS-2 Function in Tumor Progression and Metastasis
-
批准号:8106159
-
项目类别:
-
资助金额:$33.11万
-
财政年份:2010
-
负责人:LESLIE M SHAW
-
依托单位:
IRS-2 Function in Tumor Progression and Metastasis
-
批准号:7990262
-
项目类别:
-
资助金额:$34.13万
-
财政年份:2010
-
负责人:LESLIE M SHAW
-
依托单位:
IRS-2 Function in Tumor Progression and Metastasis
-
批准号:8462571
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2010
-
负责人:LESLIE M SHAW
-
依托单位:
Insulin Receptor Substrate Function in Breast Cancer
-
批准号:6431130
-
项目类别:
-
资助金额:$34.21万
-
财政年份:2002
-
负责人:LESLIE M SHAW
-
依托单位:
Insulin Receptor Substrate Function in Breast Cancer
-
批准号:6695615
-
项目类别:
-
资助金额:$34.21万
-
财政年份:2002
-
负责人:LESLIE M SHAW
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位: